ArdorComm Media Group

risks

Study Reveals Adverse Effects of Bharat Biotech’s Covaxin Vaccine

A study conducted by researchers at BHU examining the long-term effects of Bharat Biotech’s Covaxin vaccine revealed concerning findings. Out of 926 participants examined, nearly one-third reported adverse events of special interest (AESI), with viral upper respiratory tract infections being the most common complaint. Serious AESI such as stroke and Guillain-Barre syndrome were reported in one percent of individuals. The study, conducted from January 2022 to August 2023, involved 635 adolescents and 291 adults who received the Covaxin vaccine. Common AESI observed in adolescents included skin and subcutaneous disorders, general disorders, and nervous system disorders. In adults, general disorders, musculoskeletal disorders, and nervous system disorders were prevalent. The study highlighted that certain demographics faced higher risks of persistent AESIs. Females, adolescents with pre-vaccination Covid-19, people with underlying health conditions, and those who developed typhoid after vaccination had significantly higher odds of experiencing persistent AESIs. Moreover, adults with pre-existing health conditions had more than double the odds of experiencing AESIs and persistent AESIs, according to the study. Additionally, adults who received three doses of the vaccine and those who received only one dose had higher risks of AESIs compared to those who received two doses of Covaxin. These findings underscore the importance of continued monitoring and assessment of vaccine safety, particularly regarding long-term effects. Further research is needed to better understand the underlying mechanisms and risk factors associated with adverse events following Covaxin vaccination.

Study Reveals Adverse Effects of Bharat Biotech’s Covaxin Vaccine Read More »

WHO Calls for Regulation of AI in Healthcare Due to Risks, Citing Bias and Privacy Concerns

News on Health

The World Health Organization (WHO) is calling for the regulation of artificial intelligence (AI) in healthcare due to the associated risks, according to a report. WHO emphasizes the need to establish safety and efficacy in AI tools, make them accessible to those who require them, and encourage communication among AI developers and users. While recognizing AI’s potential to enhance healthcare by strengthening clinical trials, improving diagnosis and treatment, and enhancing healthcare professionals’ knowledge and skills, the report by data and analytics company GlobalData highlights the rapid deployment of AI technologies without a full understanding of their long-term implications, which could pose risks to healthcare professionals and patients. Alexandra Murdoch, a Senior Analyst at GlobalData, acknowledges the significant benefits of AI in healthcare but also highlights the risks associated with rapid adoption. AI systems in healthcare often have access to personal and medical information, necessitating regulatory frameworks to ensure privacy and security. Other challenges with AI in healthcare include unethical data collection, cybersecurity vulnerabilities, and the reinforcement of biases and dissemination of misinformation. An example of AI biases is found in a Stanford University study, which revealed that some AI chatbots provided inaccurate medical information about people of color. In this study, nine questions were posed to four AI chatbots, including OpenAI’s ChatGPT and Google’s Bard, and all four chatbots provided inaccurate information related to race and kidney and lung function. The use of such false medical information is a cause for concern, as it could lead to issues like misdiagnoses and improper treatment for patients of color. WHO has identified six areas for regulating AI in healthcare, with a focus on managing the risks associated with AI amplifying biases in training data. These areas for regulation include transparency and documentation, risk management, data validation and clarity of AI’s intended use, a commitment to data quality, privacy and data protection, and the promotion of collaboration. Alexandra Murdoch hopes that by outlining these regulatory areas, governments and regulatory bodies can develop regulations to safeguard healthcare professionals and patients while fully harnessing the potential of AI in healthcare.

WHO Calls for Regulation of AI in Healthcare Due to Risks, Citing Bias and Privacy Concerns Read More »